Overweight and obesity are increasingly recognized as potential targets for early intervention. Unlike injectable treatments, oral formulations are more easily accepted by people with diabetes. In Asian Indians, BMI ≥ 25 kg/m2 is considered obesity. Study participants were de-identified from the electronic medical records of a comprehensive diabetes centre in Kerala, India. The primary outcome variables were assessed at baseline and again at 6 months. Subjects with data spanning from March 2022 to July 2023 and a BMI ≥ 25 kg/m2 were included in the study. Those without follow-up data were excluded. Over six months, oral semaglutide (N=221) significantly reduced HbA1c by 1.38% (95% CI = 0.7 to 2.1, p < 0.001) in T2DM with BMI ≥ 25 kg/m2. A significant reduction was observed with a Mean Absolute Difference (MAD) of 2.2 kg/m2 in BMI (95% CI = 1.1 to 3.3, p < 0.001) and 4.76 kg in weight (95% CI = 2.7 to 6.8, p < 0.001). 27 participants (8%) discontinued due to side effects. (Figure). In this real world study 1 in 3 T2D with obesity achieved a weight loss of 5% and 1 in 2 T2D with obesity achieved reduction in insulin dose. This study provides real-world evidence of sustainable improvements in A1C, weight, and BMI among T2D treated with oral semaglutide.
J. Kesavadev: None. A. Shankar: None. B.D. Saboo: None. A. Ashik: None. J. Naina: None. K. Jothydev: None. A. Basanth: None. S. Raj K: None. S. Jothydev: None.
